CDC report shows decrease in US tobacco product use

Mar.23.2022
CDC report shows decrease in US tobacco product use
CDC's survey showed a decrease in overall tobacco product usage among American adults, but 19% still use some form of tobacco.

According to foreign media on March 17, 2022, report that...

 

The Centers for Disease Control and Prevention (CDC) released the findings of their weekly report on incidence and mortality rates today, revealing an overall decrease in the use of commercial tobacco products, combustible tobacco products, cigarettes, e-cigarettes, and two or more tobacco products among U.S. adults from 2019 to 2020. However, as of 2020, nearly one-fifth of adults (estimated 47.1 million) reported current (daily or some days) tobacco product use, including 30.8 million smokers.

 

In order to assess recent estimates of tobacco product use among adult Americans aged 18 and over, the Center for Disease Control and Prevention (CDC) analyzed data from the 2020 National Health Interview Survey. The survey evaluated the use of five tobacco products: cigarettes, cigars (cigars, small cigars, or filtered little cigars), pipes (regular pipes, water pipes, or hookahs), electronic cigarettes, and smokeless tobacco.

 

A recent study has found that by 2020, 19.0% of American adults will have used at least one tobacco product, which is slightly lower than the 20.8% reported in 2019. Despite this decrease, cigarettes remain the most commonly used product at 12.5%, followed by e-cigarettes at 3.7%, cigars at 3.5%, smokeless tobacco at 2.3%, and pipes at 1.1%.

 

We have made significant progress in preventing and reducing tobacco use in this country through the use of validated strategies and implementation of effective policies," said Dr. Karen Hacker, director of the CDC's National Center for Chronic Disease Prevention and Health Promotion. "Although adult tobacco use has dramatically decreased, our work is far from over. We must continue to address tobacco-related health disparities and inequities to ensure that everyone has the opportunity to be as healthy as possible.

 

Despite a decrease, the usage of combustible products remains high.

 

A new study reveals that smoking rates among adults have dropped to their lowest point since 1965, when it was 42%. While the percentage of adults who smoke has decreased from 14.0% in 2019 to 12.5% in 2020, nearly 31 million American adults still reported smoking in 2020. Among adults who currently use tobacco products, over three-quarters use combustible products like cigarettes, cigars, and pipes, which are the leading cause of tobacco-related illness, disability, and death in the United States.

 

In the United States, between 2019 and 2020, there was a decrease in the percentage of adults using other tobacco products, including e-cigarettes, which went from 4.5% to 3.7%. The use of combustible tobacco products also decreased from 16.7% to 15.2%. Additionally, the percentage of people using two or more tobacco products also decreased from 3.9% to 3.3%.

 

Factors that may contribute to a decline in smoking and tobacco use include influential anti-tobacco media campaigns such as the CDC's "Tips From Former Smokers," smoke-free policies, and policies that restrict the supply of specific types of tobacco products, such as flavored products.

 

Differences in the use of tobacco products

 

By 2020, significant differences still exist in the use of tobacco products among various adult population groups in the United States. These groups include:

 

Men (5%).

 

Nine percent of adults aged 25 to 44 years old.

 

34.9% of adult non-Hispanic American Indian/Alaska Native individuals and 1% of adult non-Hispanic individuals are classified as belonging to other races.

 

Three percent of adults live in rural (non-urban) areas.

 

The highest level of education attained by adults is a General Educational Development (GED) certificate, which accounts for 40.5%.

 

25.2% of adults have a household annual income less than $35,000.

 

Adults who identify as lesbian, gay, or bisexual (1%).

 

27.3% of adults do not have health insurance, while 6% rely on Medicaid or other forms of subsidized health insurance.

 

Four percent of adults have disabilities.

 

Nearly 30% of adults experience anxiety and 6% experience depression on a regular basis.

 

(Source: Center for Disease Control)

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Philip Morris International (PMI) has launched ZYN Melts in the UK, introducing a fully dissolvable oral nicotine tablet format alongside the brand's existing nicotine pouches. The range includes Cool Mint and Peppermint, each offered at 1mg and 2mg of nicotine per tablet, creating four SKUs. Each can contains 20 tablets and is priced at £6.50 in the UK. Unlike ZYN nicotine pouches, Melts are placed between the upper lip and gum and dissolve completely during use.
News
Sep.29 by 2Firsts Perspectives
China Tobacco Zhejiang files patent for pressure-triggered, on-demand oral nicotine release
China Tobacco Zhejiang files patent for pressure-triggered, on-demand oral nicotine release
China Tobacco Zhejiang Industrial Co., Ltd. has filed a patent application for an oral nicotine delivery product designed to let users actively adjust nicotine release. The product embeds two types of nicotine reservoirs with different wall thicknesses and positions inside a deformable matrix. Pressure applied with the tongue or lips can rupture the reservoirs and accelerate nicotine release. In simulated oral tests, several patent examples showed sharply higher peak nicotine release rates as applied force increased from 0 N to 1 N and 3 N. The filing explores a shift from preset release profiles toward user-triggered nicotine delivery.
Sep.01
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
The U.S. Department of Health and Human Services has named Bret Koplow permanent director of the FDA’s Center for Tobacco Products, ending his period as acting chief. Koplow has spent years working on tobacco regulation, law and policy inside the FDA and, while serving as acting director, pushed for faster PMTA reviews and nicotine pouch review pilots. HHS also said CTP will prioritize innovation and access to less harmful alternatives for adult smokers while continuing efforts to protect youth.
Sep.09
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India's Ministry of Health and Family Welfare has directed states to step up enforcement against nicotine pouch sales, citing increased availability through online and offline channels and concern about nicotine exposure among children. Reuters reported that international brands including ZYN and White Fox are being sold in India. A study led by ICMR-NICPR found pouches in seven of 10 surveyed locations and identified 68 brands and 445 flavors online. Separately, India's Drugs Technical Advisory Board recommended in August that no new nicotine formulation be approved.
Regulations
Sep.28 by 2Firsts Perspectives
F1 Faces Renewed Pressure Over Tobacco and Nicotine Sponsorships as 67 Groups Target ZYN and VELO Ahead of Madrid Race
F1 Faces Renewed Pressure Over Tobacco and Nicotine Sponsorships as 67 Groups Target ZYN and VELO Ahead of Madrid Race
Ahead of the Formula 1 race in Madrid, 67 Spanish and international public-health, medical and consumer organizations have sent an open letter to F1 President and CEO Stefano Domenicali calling for an end to sponsorships linked to the tobacco and nicotine industry, including nicotine pouches, vaping products and heated tobacco. The letter focuses on Philip Morris International’s ZYN partnership with Ferrari and British American Tobacco’s long-running partnership with McLaren and exposure for VELO. The campaign follows a March letter in which more than 160 organizations worldwide made a similar request to Formula 1.
Sep.10
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24